Research on the Construction and Evaluation of a CIP Prediction Model for Malignant Tumor Patients Based on Multi-modal Data Fusion AI

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2600123759

Enrollment

Unknown

Registered

2026-04-29

Start date

2026-04-30

Completion date

Unknown

Last updated

2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Checkpoint inhibitor related pneumonia (CIP)

Interventions

Control group (no CIP occurred after ICIs treatment):None

Experimental group (CIP occurred after ICIs treatment):None

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age > 18 years old; 2. Pathologically confirmed malignant tumor; 3. Receive at least one cycle of ICIs therapy; 4. Prior to receiving ICIs treatment, lung imaging and peripheral blood data were available; 5. Follow up after ICIs treatment for >= 3 months or follow-up after ICIs treatment for<3 months but confirmed occurrence of CIP with pulmonary imaging data.

Exclusion criteria

Exclusion criteria: 1. No lung imaging or peripheral blood data before receiving ICIs treatment; 2. Follow up for less than 3 months after ICIs treatment and no occurrence of CIP; 3. No pulmonary imaging data during the follow-up period.

Design outcomes

Primary

Measure	Time frame
accuracy;precision;recall;F1 score;Area under the ROC curve;	—

Countries

China

Contacts

Public ContactHaiyan Xing

Army Medical Center of PLA

9514755@qq.com+86 23 68746092

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 7, 2026